Study of 3 drugs for liver cancer that can't be removed by surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests if combining two immunotherapy drugs (atezolizumab and bevacizumab) with a brain-health medicine (memantine) can help people with advanced liver cancer that isn't treatable with surgery. It aims to see if this triple therapy works better than standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have advanced liver cancer that cannot be removed by surgery and has not been treated before.
- Your liver function must be good (Child-Pugh score A5 or A6), meaning your cirrhosis is mild.
- You must be generally active and able to take care of yourself (ECOG score 0 or 1).
- Your blood counts and kidney/liver lab results must be within certain safe ranges.
- If you are sexually active, you must use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of treatments for liver cancer that cannot be removed with surgery. It uses a procedure to block the tumor's blood supply plus two drugs that help the immune system fight the cancer. This may help shrink tumors and slow the disease.
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
This trial tests giving a low dose of two drugs (bevacizumab and atezolizumab) alongside standard local treatments (TACE and HAIC) for liver cancer that cannot be removed with surgery. The goal is to see if this combination helps control the tumor better or improves outcomes.
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
This trial tests a combination of three drugs—valemetostat, atezolizumab, and bevacizumab—for people with advanced liver cancer (HCC) who have not had systemic treatment before. The goal is to see if this combination can shrink tumors or slow disease progression.
This trial combines three medications—an immunotherapy (atezolizumab), a drug that blocks blood vessel growth (bevacizumab), and one that reduces inflammation (tocilizumab)—to see if they work together against advanced liver cancer. The goal is to slow cancer growth and possibly shrink the tumor.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.